Author:
Saintigny P.,Selle F.,Gligorov J.,Pecuchet N.,Oudet B.,Lotz J. -P.
Publisher
Computers, Materials and Continua (Tech Science Press)
Reference40 articles.
1. Arridzzoni A, Venturini M, Sertoli MR, et al. (1994) Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomized study in patients with advanced breast cancer. Br J Cancer 69: 385–391
2. Baldini E, Gardin G, Giannessi PG, et al. (2003) Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 14: 227–232
3. Basser R, O’Neill A, Martinelli, et al. (2003) Randomized trial comparing upfront, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): First results from IBCSG Trial 15–95. J Clin Oncol 22: abstract 20
4. Bergh J, Wiklund T, Erikstein B, et al. (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomized tricoll. Scandinavian Breast Group 9401 study. Lancet 356: 1384–1391
5. Buzdar AU (2007) Adjuvant chemotherapy for high-risk operable breast cancer. J Clin Oncol 25: 1642–1644